Real-world clinical outcomes among individuals with chronic HCV infection in China: CCgenos study.
This 5-year follow-up of the CCgenos cross-sectional study aimed to observe real-life outcomes in a cohort of 997 Han Chinese patients with chronic HCV infection and to explore the impacts of HCV genotype, patient characteristics, and treatment status. Clinical information and centralized HCV RNA measures were collected every 6/3 months for untreated/treated patients. Overall-disease-progression was defined as ≥1 of: de novo development of cirrhosis, Child-Turcotte-Pugh score increased by ≥2 points (if cirrhosis at baseline), progression to decompensated cirrhosis, hepatocellular carcinoma (HCC), liver transplant, or death. Cox regression assessed risk factors for the time from estimated infection to cirrhosis or HCC. Logistic regression assessed risk factors for incidence rates of cirrhosis and overall-disease-progression. 281 of 514 patients enrolled across China completed 5 years of follow-up. Overall-disease-progression occurred in 36/364 (9.9%) treated patients and 35/148 (23.6%) untreated patients (odds ratio = 0.35; 95% CI 0.21, 0.59; P < 0.0001). Overall-disease-progression occurred in 6/231 (2.6%) patients achieving SVR24 versus 11/82 (13.4%) who did not (P = 0.0002). Cirrhosis development was significantly associated with abnormal AST, age ≥40 years, BMI ≥28 kg/m2, HCV GT1, platelet count <100 × 109/L, and APRI ≥2 (multivariate Cox regression, P < 0.05). HCC was significantly associated with HCV GT1 and platelet count <100 × 109/L (multivariate Cox regression, P < 0.05). Achieving SVR24 significantly reduced the probability of overall-disease-progression but no significant difference was seen for both cirrhosis and HCC during 5 years of follow-up.